Aurinia Pharmaceuticals (FRA:IKAP) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IKAP Aurinia Pharmaceuticals Inc FRA:IKAP
80 GF Score
Price €13.81
GF Value €12.18
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

FRA:IKAP
80GF Score
Aurinia Pharmaceuticals Inc FRA:IKAP
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of €13.81 is trading 13.4% above its estimated GF Value™ of €12.18. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:IKAP:

  • FFO per Share:
  • GF Value™: €12.18 vs. price of €13.81 (13.4% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
80GF Score

Get the complete analysis for FRA:IKAP

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.81
Price
€12.18
GF Value